Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKDC | P78527 | 1/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.35 |
| ▸ | GABRA2 | P47869 | 4/20 | 0.34 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.34 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.34 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.33 |
| ▸ | FLT1 | P17948 | 1/20 | 0.33 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.33 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.33 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.33 |
| ▸ | FLT4 | P35916 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | FRS2 | Q8WU20 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30360618 | 1.00 | PRKDC (0.37) | PRKDCGPR119GABRA2FGFR1MAP4K1 | |
| SCHEMBL26516667 | 0.89 | MAP4K1 (0.39) | PRKDCGPR119MAP4K1PTGS2 | |
| SCHEMBL26516732 | 0.87 | MAP4K1 (0.41) | PRKDCMAP4K1ACVR1PTGS1PTGS2 | |
| SCHEMBL30360607 | 0.87 | MAP4K1 (0.41) | PRKDCMAP4K1ACVR1PTGS1PTGS2 | |
| SCHEMBL26516742 | 0.86 | MAP4K1 (0.40) | PRKDCGPR119GABRA2MAP4K1ACVR1 | |
| SCHEMBL30360625 | 0.84 | HRH3 (0.41) | PRKDCGPR119GABRA2FGFR1MAP4K1 | |
| SCHEMBL26516735 | 0.84 | HRH3 (0.41) | PRKDCGPR119GABRA2FGFR1MAP4K1 | |
| SCHEMBL26516688 | 0.80 | MAP4K1 (0.39) | GPR119MAP4K1ACVR1PTGS1PTGS2 | |
| SCHEMBL26516685 | 0.80 | MAP4K1 (0.39) | GPR119MAP4K1ACVR1PTGS1PTGS2 | |
| SCHEMBL30360601 | 0.75 | MAP4K1 (0.47) | GPR119MAP4K1ACVR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322770-A1 | SUBSTITUTED HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF TLR9 | BRISTOL MYERS SQUIBB CO (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230322770-A1 | SUBSTITUTED HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF TLR9 | BRISTOL MYERS SQUIBB CO (US) | 2023-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322770-A1 | SUBSTITUTED HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF TLR9 | TLR9, TLR3, TLR1 | PRKDC 1977/4885GPR119 163/4885GABRA2 3872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.